Fig 1: Effects of FN on intrahepatic lymphangiogenesis in BDL-induced PHT model. (A, B) Representative immunofluorescence double-staining images of α-SMA and LYVE-1 in portal area, and quantitative analysis of lymphangiogenesis (LYVE-1+α-SMA-) corrected for portal vein (LYVE-1-α-SMA+) area. (C) The mRNA expression of VEGF-C and VEGF-D in liver tissues of each groups. (D, E) The protein levels of VEGF-C and VEGF-D in the liver and serum determined by ELISA. Data expressed as mean ± S.E.M. Each diamond represents one biological replicate. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (One-way ANOVA with Tukey’s Test).
Fig 2: Effects of FN on the polarization of macrophages in vitro. Macrophages were exposed to varying concentrations of FN to assess its inhibitory effects on M1 polarization (induced by 50 ng/ml LPS and 40 ng/ml IFN-γ for 24 h). FN-L, 80 μM; FN-H, 160 μM. (A) CCK-8 assay of macrophages treated with FN (0-160 μM, 0–72 h). (B) Representative immunofluorescence double-staining images of iNOS and CD206, and quantitative analysis of the tendency of macrophage polarization (iNOS for M1-type and CD206 for M2-type). (C) Flow cytometry dot plots depict CD86 vs. CD206 expression in FN-treated macrophages. (D) The mRNA expression of macrophage polarization markers and VEGF-C in treated macrophages of each groups. (E) Immunoblotting of p-STAT3 (Tyr705), STAT3, p-STAT1 (Tyr701), STAT1, p-GSK3β (Ser9) and GSK3β in treated macrophages of each groups. Data expressed as mean ± S.E.M. Each diamond represents one biological replicate. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (One-way ANOVA with Tukey’s Test).
Supplier Page from BioLegend for Recombinant Human VEGF-C (carrier-free)